Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value

Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory tract infection and the leading cause of hospitalization among young children, incurring high annual costs among US children under the age of 5 years. Palivizumab has been found to be effective in reducing hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Olchanski, Natalia, Hansen, Ryan N, Pope, Elle, D’Cruz, Brittany, Fergie, Jaime, Goldstein, Mitchell, Krilov, Leonard R, McLaurin, Kimmie K, Nabrit-Stephens, Barbara, Oster, Gerald, Schaecher, Kenneth, Shaya, Fadia T, Neumann, Peter J, Sullivan, Sean D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833316/
https://www.ncbi.nlm.nih.gov/pubmed/29516023
http://dx.doi.org/10.1093/ofid/ofy031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833316/
https://www.ncbi.nlm.nih.gov/pubmed/29516023
http://dx.doi.org/10.1093/ofid/ofy031

Ejemplares similares